Positive prolactin response to bromocriptine in 2 patients with cabergoline-resistant prolactinomas

Endocrine Practice

Volumn 17, Issue 3, 2011, Pages

  Iyer, Pallavi ^a,c   Molitch, Mark E ^b  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BROMOCRIPTINE; CABERGOLINE; ESTROGEN; LEVOTHYROXINE; PROGESTERONE; PROLACTIN;

AMENORRHEA; ARTICLE; CASE REPORT; CLINICAL FEATURE; DRUG COST; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GALACTORRHEA; HEADACHE; HORMONE RESPONSE; HUMAN; HUMAN TISSUE; HYPERPROLACTINEMIA; HYPOPHYSIS ADENOMA; HYPOTHYROIDISM; LABORATORY TEST; LIBIDO DISORDER; MENSTRUATION; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARY POLYCYSTIC DISEASE; PROLACTIN BLOOD LEVEL; PROLACTINOMA; TRANSSPHENOIDAL SURGERY; TUMOR VOLUME; VALVULAR HEART DISEASE; VISUAL FIELD DEFECT; WEIGHT GAIN;

EID: 79955085743     PISSN: 1530891X     EISSN: 19342403     Source Type: Journal    
DOI: 10.4158/EP10369.CR     Document Type: Article

References (16)

1. Webster J, Piscitelli G, Polli A, Ferrari CI, Ismail I, Scanlon MF. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group. N Engl J Med. 1994;331:904-909. (Pubitemid 24299871)
2. Bevan JS, Webster J, Burke CW, Scanlon MF. Dopamine agonists and pituitary tumor shrinkage. Endocr Rev. 1992;13:220-240.
3. Di Sarno A, Landi ML, Cappabianca P, et al. Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: Prevalence, clinical definition, and therapeutic strategy. J Clin Endocrinol Metab. 2001;86:5256-5261. (Pubitemid 33070245)
4. Gillam MP, Molitch ME, Lombardi G, Colao A. Advances in the treatment of prolactinomas. Endocr Rev. 2006;27:485-534. (Pubitemid 44213229)
5. Ono M, Miki N, Kawamata T, et al. Prospective study of high-dose cabergoline treatment of prolactinomas in 150 patients. J Clin Endocrinol Metab. 2008;93:4721-4727.
6. Delgrange E, Daems T, Verhelst J, Abs R, Maiter D. Characterization of resistance to the prolactin-lowering effects of cabergoline in macroprolactinomas: A study in 122 patients. Eur J Endocrinol. 2009;160:747-752.
7. Molitch ME. The cabergoline-resistant prolactinoma patient: New challenges. J Clin Endocrinol Metab. 2008; 93:4643-4645.
8. Colao A, Di Sarno A, Landi ML, et al. Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage. J Clin Endocrinol Metab. 1997;82:3574-3579. (Pubitemid 27509339)
9. Ahmed SR, Shalet SM. Discordant responses of prolactinoma to two different dopamine agonists. Clin Endocrinol (Oxf). 1986;24:421-426. (Pubitemid 16103019)
10. Berezin M, Avidan D, Baron E. Long-term pergolide treatment of hyperprolactinemic patients previously unsuccessfully treated with dopaminergic drugs. Isr J Med Sci. 1991;27:375-379.
11. Duranteau L, Chanson P, Lavoinne A, Horlait S, Lubetzki J, Kuhn JM. Effect of the new dopaminergic agonist CV 205-502 on plasma prolactin levels and tumour size in bromocriptine-resistant prolactinomas. Clin Endocrinol (Oxf). 1991;34:25-29.
12. Razzaq R, O'Halloran DJ, Beardwell CG, Shalet SM. The effects of CV205-502 in patients with hyperprolactinaemia intolerant and/or resistant to bromocriptine. Horm Res. 1993;39:218-222. (Pubitemid 23344797)
13. Rohmer V, Freneau E, Morange I, Simonetta C. Efficacy of quinagolide in resistance to dopamine agonists: Results of a multicenter study. Club de l'Hypophyse. Ann Endocrinol (Paris). 2000;61:411-417.
14. Merola B, Sarnacchiaro F, Colao A, et al. Positive response to compound CV 205-502 in hyperprolactinemic patients resistant to or intolerant of bromocriptine. Gynecol Endocrinol. 1994;8:175-181. (Pubitemid 24316617)
15. Morange I, Barlier A, Pellegrini I, Brue T, Enjalbert A, Jaquet P. Prolactinomas resistant to bromocriptine: Long-term efficacy of quinagolide and outcome of pregnancy. Eur J Endocrinol. 1996;135:413-420. (Pubitemid 26364941)
16. Pellegrini I, Rasolonjanahary R, Gunz G, et al. Resistance to bromocriptine in prolactinomas. J Clin Endocrinol Metab. 1989;69:500-509. (Pubitemid 19221218)